{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:36:30Z","timestamp":1786984590104,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271054"],"award-info":[{"award-number":["82271054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J01012"],"award-info":[{"award-number":["2023J01012"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.apjo.2024.100104","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:39:15Z","timestamp":1727458755000},"page":"100104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real-World Large Sample Assessment of Drug-related Dry Eye Risk: Based on the FDA Adverse Event Reporting System Database"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-9059","authenticated-orcid":false,"given":"Shi-Nan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-3870","authenticated-orcid":false,"given":"Dan-Yi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfangzi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0963-0848","authenticated-orcid":false,"given":"Chang-Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-He","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2024.100104_bib1","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMra1407936","article-title":"Dry eye","volume":"378","author":"Clayton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjo.2024.100104_bib2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/09286586.2022.2131834","article-title":"Racial and ethnic disparities in dry eye diagnosis and care","volume":"30","author":"Cui","year":"2023","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.apjo.2024.100104_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/978-1-4615-0717-8_149","article-title":"Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect","volume":"506","author":"Welch","year":"2002","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.apjo.2024.100104_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.apjo.2024.100104_bib5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.4103\/IJO.IJO_2782_22","article-title":"A review on drug-induced dry eye disease","volume":"71","author":"Kam","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100104_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archopht.122.3.369","article-title":"Incidence of dry eye in an older population","volume":"122","author":"Moss","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100104_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","article-title":"Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life","volume":"157","author":"Paulsen","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100104_bib8","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.286.17.2114","article-title":"Hormone replacement therapy and dry eye syndrome","volume":"286","author":"Schaumberg","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.apjo.2024.100104_bib9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.apjo.2024.100104_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project","volume":"95","author":"Edwards","year":"2013","journal-title":"J Bone Jt Surg Am"},{"key":"10.1016\/j.apjo.2024.100104_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5582\/bst.2020.03082","article-title":"Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database","volume":"14","author":"Sato","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.apjo.2024.100104_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107818","article-title":"Thromboembolic events associated with immune checkpoint inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database","volume":"98","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apjo.2024.100104_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.apjo.2024.100104_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.apjo.2024.100104_bib15","article-title":"Drug-induced fall risk in older patients: a pharmacovigilance study of FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apjo.2024.100104_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jclinepi.2021.07.014","article-title":"A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases","volume":"139","author":"Khouri","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.apjo.2024.100104_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.apjo.2024.100104_bib18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/pds.2247","article-title":"Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and multi-item Gamma Poisson shrinker","volume":"21","author":"Berlin","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.apjo.2024.100104_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/14740338.2023.2247971","article-title":"A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system","volume":"22","author":"Wen","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.apjo.2024.100104_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtos.2018.03.002","article-title":"Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye","volume":"16","author":"Wong","year":"2018","journal-title":"Ocul Surf"},{"key":"10.1016\/j.apjo.2024.100104_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1590\/s1677-5538.ibju.2019.0094","article-title":"Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: a prospective study","volume":"46","author":"\u00d6l\u00e7\u00fcc\u00fc","year":"2020","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.apjo.2024.100104_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jdv.18843","article-title":"Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: results from a Phase 3b trial","volume":"37","author":"Szeimies","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.apjo.2024.100104_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14029","article-title":"Isotretinoin and the eye: a review for the dermatologist","volume":"33","author":"Ruiz-Lozano","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.apjo.2024.100104_bib24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/OPX.0000000000000656","article-title":"Effects of isotretinoin on Meibomian glands","volume":"92","author":"Moy","year":"2015","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.apjo.2024.100104_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTO.S355091","article-title":"A review of ocular complications associated with medications used for anxiety, depression, and stress","volume":"14","author":"Constable","year":"2022","journal-title":"Clin Optom"},{"key":"10.1016\/j.apjo.2024.100104_bib26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/ICO.0b013e3182261590","article-title":"Dry eye disease in patients with depressive and anxiety disorders in Shanghai","volume":"31","author":"Wen","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.apjo.2024.100104_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1542-0124(11)70034-9","article-title":"Non-hormonal systemic medications and dry eye","volume":"9","author":"Wong","year":"2011","journal-title":"Ocul Surf"},{"key":"10.1016\/j.apjo.2024.100104_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.apjo.2024.100104_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.survophthal.2023.09.007","article-title":"Ocular toxicities of fibroblast growth factor receptor Inhibitors: A review","volume":"69","author":"Hsu","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100104_bib30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/14740338.2023.2251380","article-title":"Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies","volume":"22","author":"Raheem","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.apjo.2024.100104_bib31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody\u2013drug conjugate Belantamab Mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.apjo.2024.100104_bib32","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of Prophylactic Corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody\u2013drug conjugate Mirvetuximab Soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apjo.2024.100104_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21873\/invivo.12674","article-title":"Ocular side effects of Aromatase inhibitor endocrine therapy in breast cancer \u2013 a review","volume":"36","author":"Serban","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.apjo.2024.100104_bib34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/cancers16020344","article-title":"Ocular surface side effects of novel anticancer drugs","volume":"16","author":"Vitiello","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.apjo.2024.100104_bib35","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2147\/OPTH.S136500","article-title":"The effect of intravitreal injections on dry eye, and proposed management strategies","volume":"11","author":"Laude","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100104_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ICO.0000000000002836","article-title":"Corneal nerve fiber and sensitivity loss after repeated intravitreal anti-VEGF injections: an in vivo confocal microscopy study","volume":"41","author":"Polat","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.apjo.2024.100104_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/15569527.2017.1291665","article-title":"Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections","volume":"36","author":"Saedon","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.apjo.2024.100104_bib38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ophtha.2023.01.009","article-title":"Associations between serial intravitreal injections and dry eye","volume":"130","author":"Malmin","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100104_bib39","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2147\/DDDT.S146556","article-title":"Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity","volume":"12","author":"Jiang","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.apjo.2024.100104_bib40","first-page":"120","article-title":"Dry eye syndrome due to botulinum toxin type-A injection: guideline for prevention","volume":"71","author":"Ozgur","year":"2012","journal-title":"Hawaii J Med Public Health"},{"key":"10.1016\/j.apjo.2024.100104_bib41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-018-4194-3","article-title":"Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines","volume":"257","author":"Choi","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100104_bib42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"73","author":"Montastruc","year":"2006","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.apjo.2024.100104_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","article-title":"An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies","volume":"39","author":"Maci\u00e1-Mart\u00ednez","year":"2016","journal-title":"Drug Saf"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098924001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098924001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:57:32Z","timestamp":1729702652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098924001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2162098924001154"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2024.100104","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Large Sample Assessment of Drug-related Dry Eye Risk: Based on the FDA Adverse Event Reporting System Database","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2024.100104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100104"}}